MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02155nam a2200241Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
NULRC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250520094925.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
250520s9999 xx 000 0 und d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780195067385 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
NULRC |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC 271.C5 .P73 1994 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Pratt, William B. |
| Relator term |
author |
| 245 #4 - TITLE STATEMENT |
|---|
| Title |
The anticancer drugs / |
| Statement of responsibility, etc. |
William B. Pratt [and three others]. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
Second edition. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
New York : |
| Name of publisher, distributor, etc. |
Oxford University Press, |
| Date of publication, distribution, etc. |
c1994 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
viii, 352 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
26 cm. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references and index. |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Principles of cancer chemotherapy -- Cancer problem -- Some milestones in the development of cancer chemotherapy -- Determinants of drug responsivveness -- Resistance to anticancer drugs -- Anticancer drugs -- Antimetabolites -- Folate antagonists, pyrimidine antagonists, purine antagonists, sugar-modified analogs, ribonucleotide reductase inhibitors -- Covalent DNA binding drugs -- Nitrogen mustards, aziridines, alkane sulfonates, nitrosoureas, platinum compounds, monoalkylating agents -- Noncovalent DNA binding drugs -- Antrhacyclines, mitoxantrone, dactinomycin, bleomycin, plicamycin -- Inhibitors of chromatin function -- Topoisomerase inhibitors, microtubule inhibitors -- Drugs affecting endocrine function -- Glucocorticoids, estrogens, antiestrogens, progestins, androgens, antiandrogens, LHRH (GnRH) agonists, aromatase inhibitors, adrenocortical suppressors -- Clinical cancer chemotherapy -- Choice of drugs for cancer chemotherapy -- Cancer treatment. (cont) New directions in cancer chemotherapy -- Anticancer drug development -- Biological treatments of cancer -- Potential targets for new anticancer drugs. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
This is an up-to-date review of the pharmacology, mechanisms of action, development of resistance, and toxicity of cancer chemotherapeutic agents. A rationale for their clinical use, based on cancer cell biology, is given for each class of drugs. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
CANCER -- CHEMOTHERAPY |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ruddon, Raymond W. ;Ensminger, William D. ;Maybaum, Jonathan |
| Relator term |
co-author;co-author;co-author |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Books |
